Back to top
more

Alkermes (ALKS)

(Delayed Data from NSDQ)

$27.32 USD

27.32
1,884,690

-0.31 (-1.12%)

Updated Jul 31, 2024 04:00 PM ET

After-Market: $27.30 -0.02 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Alkermes Gets FDA Nod for Two Month Dose of Aristada

Alkermes plc (ALKS) announced that the FDA has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.

    Arpita Dutt headshot

    Key FDA Events to Watch Out for in Jun 2017

    Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

      Alkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?

      Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss

        Alkermes plc (ALKS) reported loss of 31 cents per share (including the impact of share-based compensation expense) in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 24 cents.

          Arpita Dutt headshot

          5 Drug Stocks for Your Portfolio this World Health Day

          With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

            Alkermes Starts Phase III Study to Treat Multiple Sclerosis

            Alkermes plc (ALKS) announced the initiation of a new phase III study of pipeline candidate ALKS 8700.

              Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

              Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

                Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat

                Alkermes plc (ALKS) reported loss of 4 cents per share (including the impact of share-based compensation expense) in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 19 cents.

                  5 Drug Stocks to Avoid as Trump Vows to Lower Drug Prices

                  For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump's unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.